Home › Research › Biomarkers
Differential associations of APOE and TREM2 variants with glial fibrillary acidic protein and neurofilament light in plasma of UK Biobank participants support distinct disease mechanisms
Yun Freudenberg-Hua, Luca Giliberto, Cristina d'Abramo, Wentian Li, Yilong Ma, Alison Goate, Jeremy Koppel. Molecular psychiatry, 2025-07-15
Topic: Genetics and APOE
Plain-language summary
Plasma levels of glial fibrillary acidic protein (GFAP) and neurofilament light (NEFL) are key dementia biomarkers. GFAP and NEFL represent different underlying disease processes, i.e. astrocytic activation vs. neuronal damage. The associations of established genetic risk variants with these biomarkers may reflect time course and mechanisms by which the respective genes influence disease risk. Therefore, we investigated the association of the established high-effect dementia variants in APOE and TREM2 with these biomarkers, in a large population cohort of over 50,000 participants from the UK Biobank (UKB). The results show that APOE4 is associated with elevated levels of plasma GFAP, and to a lesser extent, NEFL. The APOE4 effect on GFAP increases with age and the number of APOE4 alleles. The risk variants R47H and R62H in TREM2 are associated with higher NEFL levels, but not with GFAP, and the effect sizes do not increase with age. In contrast, the protective APOE2 allele showed no effect on GFAP or NEFL. In conclusion, we find that major genetic risk factors for Alzheimer's disease exhibit distinct patterns of effect on these biomarkers, with APOE4 primarily affecting astrocyte activation starting in midlife, while TREM2 variants affect NEFL but not GFAP, and the protective effects of APOE2 are not captured by either of these biomarkers.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Freudenberg-Hua, Y., Giliberto, L., d'Abramo, C., Li, W., Ma, Y., Goate, A., et al. (2025). Differential associations of APOE and TREM2 variants with glial fibrillary acidic protein and neurofilament light in plasma of UK Biobank participants support distinct disease mechanisms. Molecular psychiatry. https://doi.org/10.1038/s41380-025-03098-7
Vancouver
Freudenberg-Hua Y, Giliberto L, d'Abramo C, Li W, Ma Y, Goate A, et al. Differential associations of APOE and TREM2 variants with glial fibrillary acidic protein and neurofilament light in plasma of UK Biobank participants support distinct disease mechanisms. Molecular psychiatry. 2025. doi:10.1038/s41380-025-03098-7. PMID: 40659842.
BibTeX
@article{freudenberghua2025-40659842,
author = {Freudenberg-Hua, Yun and Giliberto, Luca and d'Abramo, Cristina and Li, Wentian and Ma, Yilong and Goate, Alison and Koppel, Jeremy},
title = {{Differential associations of APOE and TREM2 variants with glial fibrillary acidic protein and neurofilament light in plasma of UK Biobank participants support distinct disease mechanisms}},
journal = {Molecular psychiatry},
year = {2025},
doi = {10.1038/s41380-025-03098-7},
pmid = {40659842},
url = {https://doi.org/10.1038/s41380-025-03098-7}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- The results show that APOE4 is associated with elevated levels of plasma GFAP, and to a lesser extent, NEFL.
- The risk variants R47H and R62H in TREM2 are associated with higher NEFL levels, but not with GFAP, and the effect sizes do not increase with age.
- In conclusion, we find that major genetic risk factors for Alzheimer's disease exhibit distinct patterns of effect on these biomarkers, with APOE4 primarily affecting astrocyte activation starting in midlife, while TREM2 variants affect NEFL but not GFAP, and the protective effects of APOE2 are not captured by either of these biomarkers.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants50,000
- Evidence strengthModerate
How this study scored 63/100
Published in a leading specialty journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 35 of the 56 points we could judge it on, which is 63 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Molecular psychiatry) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 4 / 4 | 50,000 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40659842) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 35 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 35 of the 56 points we could judge it on is 63 out of 100. |
| Total | 63 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also tagged “genetics”
346 studies in the library carry the topic tag “genetics”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 346 tagged studies.